Bryxta 100 mg Injection
  1. Home
  2. Pharma Products
  3. Cadila Healthcare Ltd
  4. Bryxta 100 mg Injection

Bryxta 100 mg Injection

Bryxta 100 mg Injection contains bevacizumab, a monoclonal antibody used in the treatment of several types of cancer. It is supplied as 100 mg/4 mL concentrate for solution for infusion and is administered by a healthcare professional. Bevacizumab blocks VEGF and helps reduce the formation of new blood vessels that support tumor growth.

BUY NOW

Category

Bryxta 100 mg Injection may be used in treatment regimens for metastatic colorectal cancer, non-small cell lung cancer, kidney cancer, cervical cancer, and certain ovarian, fallopian tube, and primary peritoneal cancers. Its active ingredient, bevacizumab, targets vascular endothelial growth factor A and restricts blood-vessel formation associated with tumor growth. The medicine is administered by intravenous infusion according to the prescribed oncology protocol. Patients should be monitored for blood pressure changes, bleeding, infusion reactions, wound-healing complications, and other treatment-related effects.

Technical Specification

Specification Details
Active Ingredient Bevacizumab
Strength 100 mg
Concentration 25 mg/mL
Dosage Form Concentrate for Solution for Infusion
Route of Administration Intravenous Infusion
Pack Size 1 Vial, 4 mL

Product Also Known As

Bryxta 100 mg Injection, Bryxta 100 Injection, Bevacizumab 100 mg Injection, Bevacizumab 100 mg/4 mL Injection, Bryxta Bevacizumab Injection, Anti-VEGF Cancer Injection